HCV Advocate Newsletter: May, 2013
In This Issue:
- The Next Wave: Janssen/Tibotec and Gilead File for FDA Approval
Alan Franciscus, Editor-in-Chief—Read about the two new HCV medications that have been submitted to the Food and Drug Administration for approval. The newer therapies promise that therapy will have fewer side effects than the current HCV protease inhibitor therapy, more convenient dosing and, for most people, a shorter treatment duration.
- HEALTHWISE: Mother's Day in the Shadow of Hepatitis C
Lucinda K. Porter, RN—In this month's column Lucinda discusses issues related to HCV and pregnancy, and HCV positive children.
Lucinda K. Porter, RN—This month's Snapshots includes the role of patient education in successful treatment, the effect of HIV on HCV disease progression, hepatitis E, and a case study on switching from telaprevir to boceprevir.
- DISABILITY & BENEFITS: Why Is Social Security Disability So Difficult to Get?
Jacques Chambers, CLU—The title says it all!
3. EASL 2013 —The EASL conference just ended. Check out our blog for information about the latest news that was released at EASL—especially all the news about the new drugs being tested to treat hepatitis C
2. HBV Journal Review by Christine Kukka —In this month's column Chris reviews the following studies. Hepatitis B is a complicated disease to understand and manage. Christine's monthly review provides much needed information to stay up to date and live healthy with hepatitis B:
Antiviral Combination Used for HIV Appears Effective In "Immune Tolerant" Patients
Despite Universal Care, Hepatitis B Care Is Inconsistent Across Canada
Home Visits Key to Promoting Hepatitis B Screening Among Ethnic Groups
Fibroscan Imaging Plus Blood Tests Could Replace Liver Biopsies
Reports Mixed as to Whether Entecavir Lowers Cancer Risk in CirrhoticPatients?
Alcoholism and Smoking Increase Liver Cancer Risk in Younger Patients
Inactive Infection and Older Age Increase HBsAg Clearance, as Do Unknown "Host" Factors
Dairy-Rich Diets Linked to Increase in Liver Cancer
3. Factsheets & Guides: New & Updated!
Be sure to check out our recently updated fact sheets and guides:
4. Clinical Trials Postings: Updated—April 24!
Be sure to check out the latest clinical trial postings at the HCV Advocate News & Pipeline Blog. Just click on the links to the Drug Companies at the top and to see which drugs are in trials right now, where the trials are, and how to register for one.
Don’t forget that there is help as close as a phone call – the 877-HELP-4-HEP line (877-435-7443) is available 9:00am to 7:00pm Eastern Time. For more information about the services they offer either call or visit their Website at www.help4hep.org The helpline is run by The Support Partnership: a group of non-profits working together to help people affected by hepatitis C.
5. Top News (Blog) from the HCV Advocate News & Pipeline Blog includes:
and much, much more…..
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org
**Questions and Comments: Questions and/or comments can be directed to email@example.com
**To receive the eblast in your email inbox simply send an e-mail to: firstname.lastname@example.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.